<VariationArchive VariationID="424065" VariationName="NM_000153.4(GALC):c.1897dup (p.Thr633fs)" VariationType="Duplication" Accession="VCV000424065" Version="8" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-20" DateCreated="2017-04-27" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="409159" VariationID="424065">
      <GeneList>
        <Gene Symbol="GALC" FullName="galactosylceramidase" GeneID="2581" HGNC_ID="HGNC:4115" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>14q31.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87933014" stop="87993667" display_start="87933014" display_stop="87993667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88399357" stop="88460008" display_start="88399357" display_stop="88460008" Strand="-" />
          </Location>
          <OMIM>606890</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000153.4(GALC):c.1897dup (p.Thr633fs)</Name>
      <CanonicalSPDI>NC_000014.9:87939918:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>14q31.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88406262" stop="88406263" display_start="88406262" display_stop="88406263" variantLength="1" positionVCF="88406262" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87939918" stop="87939919" display_start="87939918" display_stop="87939919" variantLength="1" positionVCF="87939918" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>T607fs</ProteinChange>
      <ProteinChange>T633fs</ProteinChange>
      <ProteinChange>T610fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.8" sequenceAccession="NC_000014" sequenceVersion="8" change="g.88406263dup" Assembly="GRCh37">
            <Expression>NC_000014.8:g.88406263dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.9" sequenceAccession="NC_000014" sequenceVersion="9" change="g.87939919dup" Assembly="GRCh38">
            <Expression>NC_000014.9:g.87939919dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011853.3" sequenceAccession="NG_011853" sequenceVersion="3" change="g.58645dup">
            <Expression>NG_011853.3:g.58645dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000153.4" sequenceAccession="NM_000153" sequenceVersion="4" change="c.1897dup" MANESelect="true">
            <Expression>NM_000153.4:c.1897dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000144.2" sequenceAccession="NP_000144" sequenceVersion="2" change="p.Thr633fs">
            <Expression>NP_000144.2:p.Thr633fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001201401.2" sequenceAccession="NM_001201401" sequenceVersion="2" change="c.1828dup">
            <Expression>NM_001201401.2:c.1828dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001188330.1" sequenceAccession="NP_001188330" sequenceVersion="1" change="p.Thr610fs">
            <Expression>NP_001188330.1:p.Thr610fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001201402.2" sequenceAccession="NM_001201402" sequenceVersion="2" change="c.1819dup">
            <Expression>NM_001201402.2:c.1819dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001188331.1" sequenceAccession="NP_001188331" sequenceVersion="1" change="p.Thr607fs">
            <Expression>NP_001188331.1:p.Thr607fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA16619888" DB="ClinGen" />
        <XRef Type="rs" ID="1555378538" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000153.4(GALC):c.1897dup (p.Thr633fs) AND not provided" Accession="RCV000487204" Version="2">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-05-17" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000153.4(GALC):c.1897dup (p.Thr633fs) AND Galactosylceramide beta-galactosidase deficiency" Accession="RCV001851266" Version="5">
        <ClassifiedConditionList TraitSetID="1051">
          <ClassifiedCondition DB="MedGen" ID="C0023521">Galactosylceramide beta-galactosidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-06-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-06-26" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2017-04-27" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <DescriptionHistory Dated="2022-08-22">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-08-07">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-03-25">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="1051" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Globoid cell leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Galactosylceramide beta-galactosidase deficiency</ElementValue>
                <XRef ID="Krabbe+leukodystrophy/4044" DB="Genetic Alliance" />
                <XRef ID="192782005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Krabbe leukodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, Globoid Cell</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GCL</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GLD</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</Attribute>
                <XRef ID="NBK1238" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6844" />
                <XRef ID="6844" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301416</ID>
                <ID Source="BookShelf">NBK1238</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, elevated psychosine, Krabbe Disease (infantile form), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Krabbe disease: galactocerebrosidase deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, mildly elevated psychosine, Krabbe Disease (late-onset form), 2022</CitationText>
              </Citation>
              <XRef ID="487" DB="Orphanet" />
              <XRef ID="C0023521" DB="MedGen" />
              <XRef ID="MONDO:0009499" DB="MONDO" />
              <XRef Type="MIM" ID="245200" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1108949" SubmissionDate="2019-01-29" DateLastUpdated="2019-04-17" DateCreated="2017-04-27">
        <ClinVarSubmissionID localKey="GDX:1501092|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000573842" DateUpdated="2019-04-17" DateCreated="2017-04-27" Type="SCV" Version="4" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-05-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>The c.1897dupA variant in the GALC gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The c.1897dupA variant causes a frameshift starting with codon Threonine 633, changes this amino acid to a Asparagine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Thr633AsnfsX5. This variant is predicted to cause loss of normal protein function through protein truncation. The c.1897dupA variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The c.1897dupA variant is a strong candidate for a pathogenic variant, however the possibility it may be a rare benign variant cannot be excluded.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="14" alternateAllele="TT" referenceAllele="T" start="88406262" stop="88406263" variantLength="2" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000153.3:c.1897dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4147095" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="3497241|MedGen:C0023521" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002133355" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant has not been reported in the literature in individuals with GALC-related conditions. ClinVar contains an entry for this variant (Variation ID: 424065). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the GALC protein. Other variant(s) that disrupt this region (p.Lys648*) have been determined to be pathogenic (Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Thr633Asnfs*5) in the GALC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 53 amino acid(s) of the GALC protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000014.8:g.88406262_88406263insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023521" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1108949" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4147095" TraitType="Disease" MappingType="XRef" MappingValue="C0023521" MappingRef="MedGen">
        <MedGen CUI="C0023521" Name="Galactosylceramide beta-galactosidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

